Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Arbutus Biopharma Corp(ABUS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABUS
09/18/2026: ABUS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Arbutus Biopharma is a clinical-stage biotechnology company focused on developing a functional cure for chronic hepatitis B. Its primary strength lies in its specialized pipeline, notably the RNAi therapeutic imdusiran, supported by a significant intellectual property portfolio in lipid delivery. The company offers investors a high-risk, high-reward opportunity centered on clinical milestones and potential licensing deals. However, it faces substantial risks, including binary trial outcomes, intense competition from well-capitalized pharmaceutical giants, and a lack of recurring commercial revenue. The stock is best suited for growth-oriented investors with a high risk tolerance who are closely monitoring clinical trial data and legal updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Arbutus offers high-risk, high-reward potential tied to clinical breakthroughs in hepatitis B. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience significant moves based on clinical trial catalysts and intellectual property news. |
| Value investor | Weak fit | As a loss-making clinical-stage company, traditional value metrics are not applicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and has no recurring commercial revenue. |
| Low-risk investor | Weak fit | The company's focus on clinical-stage biotechnology carries significant binary risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical outcomes and legal rulings cause rapid and extreme price movements. |
| Valuation risk | High | Valuation is speculative and heavily dependent on future successful commercialization of candidates. |
| Competition risk (Hepatitis B treatment) | High | Large pharmaceutical competitors have significantly more resources and established commercial pipelines. |
| Business quality | Medium | The company relies on specific scientific breakthroughs and legal intellectual property assets. |
| Dividend income | Low / none | There is no income generation for shareholders. |
| Execution risk | High | Success depends entirely on the outcome of clinical trials and regulatory approval processes. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -4.66% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/18/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.00B USD | Price to earnings Ratio 6.42 | 1Y Target Price 5.45 |
Price to earnings Ratio 6.42 | 1Y Target Price 5.45 | ||
Volume (30-day avg) 4.2M shares | Beta 0.62 | 52 Weeks Range 3.50 - 5.45 | Updated Date 09/18/2026 |
52 Weeks Range 3.50 - 5.45 | Updated Date 09/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.79 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| License and Collaboration Revenue | Milestone payments and royalties from third-party use of its proprietary intellectual property. | Revenue is sporadic and depends on successful partnerships and licensing agreements. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 6.42 | Forward PE 10.25 | Enterprise Value 908.32M | Price to Sales(TTM) 5.53 |
Enterprise Value 908.32M | Price to Sales(TTM) 5.53 | ||
Enterprise Value to Revenue 4.99 | Enterprise Value to EBITDA 5.92 | Shares Outstanding 198.11M | Shares Floating 122.66M |
Shares Outstanding 198.11M | Shares Floating 122.66M | ||
Percent Insiders 20.4 | Percent Institutions 72.71 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquarters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.arbutusbio.com |
Full time employees 19 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.